NO20003211L - Triazinforbindelser for behandling av CNS forstyrrelser - Google Patents

Triazinforbindelser for behandling av CNS forstyrrelser

Info

Publication number
NO20003211L
NO20003211L NO20003211A NO20003211A NO20003211L NO 20003211 L NO20003211 L NO 20003211L NO 20003211 A NO20003211 A NO 20003211A NO 20003211 A NO20003211 A NO 20003211A NO 20003211 L NO20003211 L NO 20003211L
Authority
NO
Norway
Prior art keywords
treatment
cns disorders
triazine compounds
triazine
cns
Prior art date
Application number
NO20003211A
Other languages
English (en)
Other versions
NO20003211D0 (no
Inventor
Brian Cox
Mark Patrick Healy
Malcolm Stuart Nobbs
Gita Punjabhai Shah
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20003211D0 publication Critical patent/NO20003211D0/no
Publication of NO20003211L publication Critical patent/NO20003211L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En forbindelse ifølge formel (I) og farmasøytisk akseptable promedikamenter, salter og solvater derav er beskrevet.
NO20003211A 1997-12-22 2000-06-21 Triazinforbindelser for behandling av CNS forstyrrelser NO20003211L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9726987.2A GB9726987D0 (en) 1997-12-22 1997-12-22 Compounds
PCT/EP1998/008273 WO1999032462A1 (en) 1997-12-22 1998-12-18 Triazine compounds for treatment of cns disorders

Publications (2)

Publication Number Publication Date
NO20003211D0 NO20003211D0 (no) 2000-06-21
NO20003211L true NO20003211L (no) 2000-08-21

Family

ID=10823992

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003211A NO20003211L (no) 1997-12-22 2000-06-21 Triazinforbindelser for behandling av CNS forstyrrelser

Country Status (34)

Country Link
US (2) US6265405B1 (no)
EP (1) EP1042304A1 (no)
JP (1) JP2001526275A (no)
KR (1) KR20010024800A (no)
CN (1) CN1284951A (no)
AP (1) AP2000001846A0 (no)
AR (1) AR014146A1 (no)
AU (1) AU753874B2 (no)
BR (1) BR9814495A (no)
CA (1) CA2315620A1 (no)
CO (1) CO5011066A1 (no)
EA (1) EA200000561A1 (no)
EE (1) EE200000391A (no)
GB (1) GB9726987D0 (no)
GT (1) GT199800203A (no)
HN (1) HN1998000193A (no)
HR (1) HRP20000419A2 (no)
HU (1) HUP0100611A3 (no)
ID (1) ID25449A (no)
IL (1) IL136867A0 (no)
IS (1) IS5542A (no)
JO (1) JO2065B1 (no)
MA (1) MA26587A1 (no)
NO (1) NO20003211L (no)
NZ (1) NZ505254A (no)
PA (1) PA8465101A1 (no)
PE (1) PE20000063A1 (no)
PL (1) PL341392A1 (no)
SK (1) SK9592000A3 (no)
SV (1) SV1998000151A (no)
TR (1) TR200001970T2 (no)
WO (1) WO1999032462A1 (no)
YU (1) YU39600A (no)
ZA (1) ZA9811725B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0002666D0 (en) 2000-02-04 2000-03-29 Univ London Blockade of voltage dependent sodium channels
ES2286328T3 (es) * 2001-12-27 2007-12-01 Ortho-Mcneil Pharmaceutical, Inc. Aroilpirrolheteroaril y metanoles utiles para tratar transtornos del sistema nervioso central.
CN100363007C (zh) * 2002-07-29 2008-01-23 葛兰素集团有限公司 含拉莫三嗪的缓释制剂
JP2006515326A (ja) * 2003-01-30 2006-05-25 ダイノジェン ファーマシューティカルズ， インコーポレイテッド 胃腸管障害を処置するためのナトリウムチャネルモジュレーターの使用
MY142651A (en) 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
DE10332472A1 (de) * 2003-07-16 2005-02-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol für die Behandlung von Tinnitus
ES2339021T3 (es) * 2003-08-25 2010-05-14 Newron Pharmaceuticals S.P.A. Derivados de alfa-aminoamida utiles como agentes antiinflamatorios.
US20060115865A1 (en) * 2004-10-25 2006-06-01 Anlong Ouyang Lamotrigine analogs
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
TWI651310B (zh) 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途
TWI704139B (zh) 2015-08-17 2020-09-11 日商日本煙草產業股份有限公司 羥基三化合物及其醫藥用途
EP3524605B1 (en) * 2018-02-13 2019-11-27 F.I.S.- Fabbrica Italiana Sintetici S.p.A. New efficient process for the preparation of sitagliptin
CN114796146B (zh) * 2022-04-28 2023-03-28 上海奥科达医药科技股份有限公司 一种拉莫三嗪的缓释制剂及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3637688A (en) 1970-01-09 1972-01-25 American Home Prod 6-(fluoro and trifluoromethyl phenyl)-3 5-diamino - 1 2 4 - triazines and substituted - 6 - phenylalkyl-3,5-diamino-1 2 4-triazines
JPS5625170A (en) 1979-06-01 1981-03-10 Wellcome Found Triazine derivative
EP0021121B1 (en) * 1979-06-01 1983-05-11 The Wellcome Foundation Limited 1,2,4-triazine derivatives, process for preparing such compounds and pharmaceutical compositions containing them
IT1145308B (it) 1979-08-16 1986-11-05 Wellcome Found Composti aromatici sostituiti
GB8328757D0 (en) 1983-10-27 1983-11-30 Wellcome Found Chemical compounds
GB9012311D0 (en) 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
GB9012312D0 (en) 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
GB9012316D0 (en) 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
GB9203483D0 (en) 1992-02-19 1992-04-08 Wellcome Found Anti-inflammatory compounds
AU688729B2 (en) 1992-06-12 1998-03-19 Wellcome Foundation Limited, The Use of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine isethionate for the treatment and prevention of dependence, tolerance and sensitization of drugs
JPH08504798A (ja) 1992-12-18 1996-05-21 ザ ウエルカム ファウンデーション リミテッド 酵素阻害薬としての，ピリミジン，ピリジン，プテリジノンおよびインダゾール誘導体
US5866597A (en) 1993-03-19 1999-02-02 Glaxo Wellcome Inc. Use of triazine compounds for the treatment of memory and learning disorders
GB9305692D0 (en) 1993-03-19 1993-05-05 Wellcome Found Therapeutic triazine compounds and use
GB9426448D0 (en) * 1994-12-30 1995-03-01 Wellcome Found Process
FR2741879A1 (fr) 1995-12-05 1997-06-06 Esteve Labor Dr Derives de fluorophenyl-triazines et pyrimidines, leur preparation et leur application en tant que medicament

Also Published As

Publication number Publication date
HUP0100611A2 (hu) 2001-09-28
US6265405B1 (en) 2001-07-24
AU2414799A (en) 1999-07-12
ZA9811725B (en) 2000-06-27
GT199800203A (es) 2000-06-14
IS5542A (is) 2000-06-20
SK9592000A3 (en) 2001-03-12
WO1999032462A1 (en) 1999-07-01
AR014146A1 (es) 2001-02-07
AP2000001846A0 (en) 2000-06-30
IL136867A0 (en) 2001-06-14
NZ505254A (en) 2002-06-28
GB9726987D0 (en) 1998-02-18
HN1998000193A (es) 2000-04-05
ID25449A (id) 2000-10-05
EA200000561A1 (ru) 2001-04-23
EE200000391A (et) 2002-02-15
SV1998000151A (es) 1999-07-05
NO20003211D0 (no) 2000-06-21
EP1042304A1 (en) 2000-10-11
CA2315620A1 (en) 1999-07-01
HRP20000419A2 (en) 2000-12-31
PA8465101A1 (es) 2000-09-29
AU753874B2 (en) 2002-10-31
TR200001970T2 (tr) 2001-01-22
CO5011066A1 (es) 2001-02-28
PE20000063A1 (es) 2000-02-16
US6465461B1 (en) 2002-10-15
MA26587A1 (fr) 2004-12-20
JO2065B1 (en) 2000-05-21
HUP0100611A3 (en) 2003-03-28
JP2001526275A (ja) 2001-12-18
CN1284951A (zh) 2001-02-21
YU39600A (sh) 2002-11-15
KR20010024800A (ko) 2001-03-26
BR9814495A (pt) 2000-10-10
PL341392A1 (en) 2001-04-09

Similar Documents

Publication Publication Date Title
MY117896A (en) Quinazoline derivatives
GB0111523D0 (en) Chemical compounds
SG128491A1 (en) Heterocyclic sulfonamide inhibitors of beta amyloid production
MX9707980A (es) Derivados de 4-aminoquinazolina, composiciones que los contienen, y uso de los mismos.
MY136685A (en) Thiazole derivatives for treating ppar related disorders
IL107184A (en) Heterocyclic ether compounds that enhance cognitive function
BG106586A (en) Pyrazolopyramidines as therapeutic agents
GEP20064005B (en) Use of novel benzoimidazole derivatives as antiproliferative agents
GB9801690D0 (en) Therapeutic agents
BG106493A (en) Heteropolycyclic compounds and their use as metabotropic glutamate receptor
NO972307L (no) Matriksmetallproteaseinhibitorer
CA2226292A1 (en) Substituted benzolactam compounds as substance p antagonists
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
MXPA02009706A (es) Metodo para sintesis de perindopril y sus sales farmaceuticamente aceptables.
NO996108L (no) 9-oksinerytromycinderivater
PL338352A1 (en) Derivatives of 1-(n-phenylaminoalkyl)-piperazine substituted at position 2 of its phenyl ring
NO20015172L (no) 1-metyl-erytromycin-derivater
AP2000001846A0 (en) Triazine compounds for treatment of CNS disorders.
JO1704B1 (en) New potent compounds
NO930520L (no) Bifenyl-substituerte kinolinderivater
IL114754A0 (en) Benzimidazole derivatives
BG104575A (en) Matrix metalloprotease inhibitors
NO981393L (no) Guanidinoproteasehemmere
WO1999038841A8 (en) Adamantanecarboximidamide derivatives and their use as nmda antagonists
AU2287499A (en) Azetidinecarboxamide derivatives for treating cns disorders